Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 04 Apr 2022 for Cidara Therapeutics, Inc.. Read the official filing
Filing timeline
BuySaleBrady Johnson
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Brady Johnson: trading record in brief
This profile gathers the share dealings of Brady Johnson in Cidara Therapeutics, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 30 September 2021 to 31 March 2022, the count stands at 6 filings.
No open-market purchase appears, only 2 sales worth €1,089. Outside the open market, there are 3 share grants and 1 option exercise. So far in 2022, the count stands at no purchases and 2 sales.
The latest filing, published on 4 April 2022, reports a share grant in Cidara Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Brady Johnson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
10,000 shares0Common StockSEC:0001610618-22-000031:0
654 shares@ US$0.8144.1% of flowCommon StockSEC:0001610618-22-000015:0
945 shares@ US$0.7155.9% of flowCommon StockSEC:0001610618-22-000013:0
262 shares0Common StockSEC:0001209191-22-002602:0
20,750 shares0Common StockSEC:0001610618-21-000097:0
20,750 shares0Common StockSEC:0001610618-21-000095:0
6 of 6 declarations
